Skip to main content

Table 1 Summary of pharmacokinetic profiles for omalizumab [4, 5], mepolizumab [7, 10, 16] and reslizumab [6, 9]

From: The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review

  Omalizumab Mepolizumab Reslizumab
Route SC SC IV IV
Absolute bioavailability 100% 100%
Tmax 7–8 days 4–8 days End of infusion End of infusion
Vd 78 mL/kg 51 mL/kg 55–85 mL/kg ≈5 L
CLS 2.4 mL/kg/day 3.1 mL/kg/day 1.9–3.3 mL/kg/day ≈7 mL/hour
t½ 26 days 16–22 days ≈20 days ≈24 days
  1. CLS systemic clearance, IV intravenous, PK pharmacokinetics, SC subcutaneous, t½ elimination half-life, Tmax time to Cmax, Vd volume of distribution